Evidence map›Paper›PMID 40553275›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Synergy Assay for Screening Small Molecule Combinations in Brain Cancer Stem Cells.

Benjamin Brakel, Iqra Chaudhry, Chitra Venugopal, Sheila K Singh

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Benjamin BrakelCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
Iqra ChaudhryCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
Chitra VenugopalCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
Sheila K SinghCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada. ssingh@mcmaster.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain tumors are among the most heterogeneous tumors characterized. This heterogeneity drives resistance to single-drug therapies, making combination treatment a more promising approach to improve treatment outcomes. To optimize drug combinations and guide treatment development in this new era of combinatorial therapy, methods for quantifying synergistic, additive or antagonistic interactions between treatments are needed. In this chapter, we describe an in vitro assay to identify synergistic drug combinations in brain-tumor-derived cell cultures. As the gold-standard assay for the in vitro evaluation of drug combination efficacy, this protocol is a fast, inexpensive, and highly reproducible method for identifying and validating synergistic drug combinations.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsNeoplastic Stem CellsSmall Molecule LibrariesCell Line, TumorDrug Screening Assays, AntitumorDrug SynergismHumansAntineoplastic AgentsSmall Molecule LibrariesCombinatorial treatmentDrug assaysProliferationSynergy

Identifiers

PMID40553275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.